Outcomes of pediatric patients with malignant extracranial germ cell tumors at a tertiary care hospital in Mexico
Clicks: 2
ID: 309988
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #470 of 490 articles by views in Frontiers in surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 490 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
IntroductionGerm Cell Tumors (GCT) are the second most common malignancy in adolescence. Extracranial malignant GCT (eGCT) are much more common among adolescents, representing approximately 15% of cancer diagnoses in this age group. Treatment for these tumors involves surgery, chemotherapy, and radiotherapy. Total tumor resection is a primary prognostic factor. The most common treatment regimen consists of bleomycin, etoposide, and cisplatin. In Latin America, data are scarce. Some reports show that the most frequent age of presentation is in adolescents aged 15–19 years.Material and methodsA retrospective study was conducted from January 2014 to December 2024, accepting 60 newly diagnosed patients with malignant eGCT at a tertiary care hospital in Mexico. The chemotherapy regimens used were CISCA II and BEP. We performed descriptive statistics, as well as Kaplan–Meier survival analysis.ResultsThe mean patient age was 10.5 + 4.5 years. The adolescent group was the most significant (48.3% of the total of all patients). The most common histology was mixed tumor in 35% of patients. The most frequent primary site was the gonadal region in 95% of patients; 53.3% of patients presented in advanced stages III and IV. The overall survival rate was 94.9%, and the relapse-free survival rate was 88.5%. Three deaths were recorded in 10 years. Five patients with hypoacusis were recorded, and in one case, a decrease in the LVEF was observed, with no change in functional class.ConclusionsIn conclusion eGCT are highly curable diseases. In this series of cases, good long-term results were observed.
| Reference Key |
imported_1768907763_696f63f3adc6d
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Dorantes-Acosta, Elisa |
| Journal | Frontiers in surgery |
| Year | 2026 |
| DOI |
10.3389/fradm.2025.1718457
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.